Cytomed Therapeutics LTD (GDTC) — 6-K Filings

6-K Filings (26)

• 6-K Filing — Apr 14, 2026
• CytoMed Therapeutics Files 6-K Report — Mar 31, 2026 Risk: low
  CytoMed Therapeutics Ltd filed a Form 6-K on March 31, 2026, reporting as a foreign issuer. The filing includes the standard 6-K report document and a complete
• CytoMed Therapeutics to Explore Phase I Trial with Universiti Malaya — Dec 8, 2025 Risk: medium
  On December 8, 2025, CytoMed Therapeutics Limited announced it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre. This collaboratio
• CytoMed Acquires TC BioPharm Assets for Cancer Treatment — Nov 18, 2025 Risk: medium
  On November 18, 2025, CytoMed Therapeutics Limited announced the completion of its acquisition of synergistic assets from TC BioPharm Limited. These assets are
• 6-K Filing — Nov 6, 2025
• CytoMed Chairman Buys More Shares — Oct 22, 2025 Risk: low
  On October 22, 2025, CytoMed Therapeutics Limited announced that its Executive Chairman and substantial shareholder, Mr. Choo Chee Kong, increased his stake in
• CytoMed Therapeutics Bids for TC BioPharm Assets — Oct 14, 2025 Risk: medium
  On October 14, 2025, CytoMed Therapeutics Limited announced it has submitted an undisclosed cash bid for potentially synergistic assets of TC BioPharm Limited (
• CytoMed Therapeutics AML Research Published — Oct 2, 2025 Risk: medium
  On October 2, 2025, CytoMed Therapeutics Limited announced a publication detailing collaborative research with The University of Texas, MD Anderson Cancer Cente
• CytoMed Therapeutics Files 6-K for Period Ending 06/30/2025 — Sep 30, 2025 Risk: low
  CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K report for the financial period ended June 30, 2025. The company, incorp
• CytoMed Expands NK Cell Production, Plans New Cord Blood Biotech — Aug 28, 2025 Risk: medium
  On August 28, 2025, CytoMed Therapeutics Limited announced its expansion into clinical-scale natural killer (NK) cell production derived from cord blood, in add
• CytoMed Therapeutics Signs At-the-Market Sales Agreement — Aug 19, 2025 Risk: medium
  On August 18, 2025, CytoMed Therapeutics Limited entered into an at-the-market sales agreement with R.F. Lafferty & Co., Inc. as sales agent. This agreement all
• CytoMed Therapeutics Issues Press Release — Jul 21, 2025 Risk: low
  On July 21, 2025, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of this
• CytoMed Therapeutics Holds Annual Shareholders Meeting — Jul 3, 2025 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on July 3, 2025, reporting on events for the month of July 2025. The filing indicates that the company held its An
• CytoMed Therapeutics Files 6-K for Annual Shareholder Meeting — May 16, 2025 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on May 16, 2025, to report information related to its upcoming annual general meeting of shareholders. The filing
• CytoMed Therapeutics Ltd. Files January 2025 6-K Report — Jan 6, 2025 Risk: low
  On January 6, 2025, CytoMed Therapeutics Limited announced its financial results for the period ending December 31, 2024. The company, formerly known as CytoMed
• CytoMed Therapeutics Reports Rise in Collaborations — Dec 5, 2024 Risk: low
  CytoMed Therapeutics Limited, formerly CytoMed Therapeutics Pte. Ltd., filed a Form 6-K on December 5, 2024. The company, incorporated in Singapore with its pri
• CytoMed Therapeutics Ltd. Files Form 6-K — Nov 20, 2024 Risk: low
  On November 20, 2024, CytoMed Therapeutics Limited issued a press release. The company's former name was CytoMed Therapeutics Pte. Ltd., with a name change occu
• CytoMed Therapeutics Announces Press Release — Oct 7, 2024 Risk: low
  On October 7, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details about the content of thi
• CytoMed Therapeutics Issues Press Release — Oct 3, 2024 Risk: low
  On October 3, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of
• CytoMed Therapeutics Files 6-K for June 30, 2024 Period — Sep 30, 2024 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on September 30, 2024, reporting for the financial period ended June 30, 2024. The company, previously known as Cy
• CytoMed Therapeutics Announces Board Re-organization — Jun 20, 2024 Risk: low
  CytoMed Therapeutics Ltd. filed a Form 6-K on June 20, 2024, reporting a board re-organization. This action is in accordance with Regulation 117 of the Company'
• CytoMed Therapeutics Holds Annual Shareholders Meeting — May 24, 2024 Risk: low
  CytoMed Therapeutics Limited held its Annual Shareholders Meeting on May 15, 2024, at 11:00 a.m. local time. The company is a foreign private issuer filing a Fo
• CytoMed Therapeutics Files 6-K for Proxy Statement — Apr 24, 2024 Risk: low
  CytoMed Therapeutics Limited filed a Form 6-K on April 24, 2024, to provide its proxy statement and notice of an annual general meeting. The company, incorporat
• CytoMed Therapeutics Issues Press Release — Mar 18, 2024 Risk: low
  On March 18, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of
• CytoMed Therapeutics Issues March 4 Press Release — Mar 4, 2024 Risk: low
  On March 4, 2024, CytoMed Therapeutics Limited announced the issuance of a press release. The filing does not contain further details regarding the content of t
• CytoMed Secures Malaysian Patent for Cancer-Targeting T-Cell Tech — Jan 29, 2024
  CytoMed Therapeutics Ltd. announced on January 29, 2024, that the Intellectual Property Corporation of Malaysia granted a patent (Application No.: PI2019004561,

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX